Acadia Pharmaceuticals Inc (ACAD) stock
ACADNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3027% below fair value
$18.32−0.35 (-1.87%)
Close on Nov 17, 2026Market cap $3.16BP/E 8.3Yield –
Acadia Pharmaceuticals price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Acadia Pharmaceuticals's price to sales ratio was 2.8× on Nov 11, 2026, against 4.0× a year earlier. Over the last 5 years it ranged from 2.5× to 9.1×, with a median of 4.3×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 2.8× | −1.5 |
| 2025 | Dec 31, 2025 | 4.3× | +1.0 |
| 2024 | Dec 31, 2024 | 3.3× | −4.8 |
| 2023 | Dec 29, 2023 | 8.1× | +3.1 |
| 2022 | Dec 30, 2022 | 5.0× | −2.9 |
| 2021 | Dec 31, 2021 | 7.9× | −12.4 |
| 2020 | Dec 31, 2020 | 20.3× | −1.6 |
| 2019 | Dec 31, 2019 | 21.9× | +12.1 |
| 2018 | Dec 31, 2018 | 9.7× | −29.9 |
| 2017 | Dec 29, 2017 | 39.6× | −361.7 |
| 2013 | Oct 31, 2013 | 401.3× | +349.8 |
| 2012 | Dec 31, 2012 | 51.4× | +49.9 |
| 2011 | Dec 30, 2011 | 1.5× | −5.5 |
| 2010 | Dec 31, 2010 | 7.0× | – |
See a number that looks wrong?